
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About


Neuropace Inc (NPCE)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: NPCE (3-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $16.75
1 Year Target Price $16.75
6 | Strong Buy |
2 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 181.14% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 301.37M USD | Price to earnings Ratio - | 1Y Target Price 16.75 |
Price to earnings Ratio - | 1Y Target Price 16.75 | ||
Volume (30-day avg) 8 | Beta 1.9 | 52 Weeks Range 5.45 - 18.98 | Updated Date 08/29/2025 |
52 Weeks Range 5.45 - 18.98 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.82 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-12 | When - | Estimate -0.22 | Actual -0.26 |
Profitability
Profit Margin -29.29% | Operating Margin (TTM) -29.01% |
Management Effectiveness
Return on Assets (TTM) -12.39% | Return on Equity (TTM) -176.94% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 310750446 | Price to Sales(TTM) 3.4 |
Enterprise Value 310750446 | Price to Sales(TTM) 3.4 | ||
Enterprise Value to Revenue 3.51 | Enterprise Value to EBITDA -16.94 | Shares Outstanding 33081500 | Shares Floating 22523207 |
Shares Outstanding 33081500 | Shares Floating 22523207 | ||
Percent Insiders 2.71 | Percent Institutions 82.15 |
Upturn AI SWOT
Neuropace Inc

Company Overview
History and Background
NeuroPace, Inc. was founded in 1997 and is a commercial-stage medical device company focused on developing and commercializing innovative therapies to treat neurological disorders, primarily epilepsy. The company's initial focus was on developing the RNS System.
Core Business Areas
- Neuromodulation: Developing and commercializing the RNS System for responsive neuromodulation to treat epilepsy. This is their core business.
Leadership and Structure
The leadership team includes Michael Favet, CEO, and various VPs overseeing different departments. NeuroPace has a typical corporate structure with a board of directors and executive management.
Top Products and Market Share
Key Offerings
- RNS System: The RNS System is the company's primary product. It is a closed-loop responsive neurostimulation system designed to prevent seizures by delivering targeted electrical stimulation to the seizure focus in the brain. Competitors would be other epilepsy treatments like medication, surgery, or alternative neuromodulation devices (e.g., vagus nerve stimulation, deep brain stimulation).
Market Dynamics
Industry Overview
The neuromodulation market is growing, driven by increasing prevalence of neurological disorders and advancements in technology. Epilepsy treatment represents a significant segment of this market.
Positioning
NeuroPace is positioned as a leader in responsive neuromodulation for epilepsy. The RNS System is the only FDA-approved closed-loop neurostimulation system for epilepsy.
Total Addressable Market (TAM)
The total addressable market for epilepsy treatments is estimated to be billions of dollars. NeuroPace is targeting a subset of this market, specifically patients with drug-resistant epilepsy who are not suitable for other surgical interventions. The TAM for RNS system could be in the hundreds of millions to low billions.
Upturn SWOT Analysis
Strengths
- FDA-approved technology
- First-mover advantage in responsive neurostimulation
- Demonstrated efficacy in clinical trials
- Proprietary technology
Weaknesses
- High cost of the RNS System
- Complex implantation procedure
- Limited market penetration to date
- Dependence on a single product
Opportunities
- Expanding indications for the RNS System
- Increasing awareness and adoption of responsive neuromodulation
- Developing next-generation neuromodulation technologies
- Partnerships with hospitals and epilepsy centers
Threats
- Competition from other epilepsy treatments
- Reimbursement challenges
- Technological advancements by competitors
- Regulatory changes
Competitors and Market Share
Key Competitors
- MRK
- ABT
- BSX
Competitive Landscape
NeuroPace has an advantage with its closed-loop system but faces competition from established players like Medtronic (MRK) and Abbott (ABT) in the broader neuromodulation market.
Growth Trajectory and Initiatives
Historical Growth: NeuroPace's growth has been dependent on RNS System adoption and revenue generation.
Future Projections: Analyst projections estimate continued revenue growth driven by increased adoption of the RNS System.
Recent Initiatives: Recent initiatives likely include expanding sales and marketing efforts, conducting clinical trials for new indications, and developing next-generation technologies.
Summary
NeuroPace is a promising medical device company with a unique technology for treating epilepsy. The company's strength lies in its FDA-approved RNS System and first-mover advantage. However, the high cost and complex implantation pose challenges. Expanding indications and partnerships could drive future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- NeuroPace Investor Relations
- SEC Filings (10K, 10Q)
- Analyst Reports
- Company Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate. Financial data needs to be updated with the latest quarterly filings.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuropace Inc
Exchange NASDAQ | Headquaters Mountain View, CA, United States | ||
IPO Launch date 2021-04-22 | CEO, President & Director Mr. Joel D. Becker | ||
Sector Healthcare | Industry Medical Devices | Full time employees 209 | Website https://www.neuropace.com |
Full time employees 209 | Website https://www.neuropace.com |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.